Skip to content

Released Feb 27, 2023, before the open

10-K filed Feb 27, 2023, 58 days after period end · 0001558370-23-002102

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$8.62Mderived+0.8% vs Q4 2021−39.2% vs Q3 2022
Net Income-$3.74MderivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$2,495,000N/M
Operating Cash Flowderived-$2,611,000N/M
Free Cash Flowderived-$2,824,000N/M
Margins · derived
Operating margin-29.0%+37.8 pt vs Q4 2021
Net margin-43.4%+34.6 pt vs Q4 2021

What the release said

The release

Same quarter

MetricQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figuresQ4 2019
Revenue$8.62M$8.55M$19.50M$17.76M
Net Income-$3.74M-$6.67M$397.00K$291.00K
EPS Diluted———$0.02

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR